These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1976795)

  • 1. On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection.
    Machado SG; Gail MH; Ellenberg SS
    J Acquir Immune Defic Syndr (1988); 1990; 3(11):1065-73. PubMed ID: 1976795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials.
    Lin DY; Fischl MA; Schoenfeld DA
    Stat Med; 1993 May; 12(9):835-42. PubMed ID: 8101011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surrogate markers in AIDS and cancer trials.
    Fleming TR
    Stat Med; 1994 Jul 15-30; 13(13-14):1423-35; discussion 1437-40. PubMed ID: 7973222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties.
    Lagakos SW
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S22-5. PubMed ID: 8093844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of large, simple trials in the evaluation of AIDS treatment strategies.
    Ellenberg SS; Foulkes MA
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):405-15. PubMed ID: 7912842
    [No Abstract]   [Full Text] [Related]  

  • 6. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.
    Choi S; Lagakos SW; Schooley RT; Volberding PA
    Ann Intern Med; 1993 May; 118(9):674-80. PubMed ID: 8096373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.
    Sánchez-Ramón S; Bellón JM; Resino S; Cantó-Nogués C; Gurbindo D; Ramos JT; Muñoz-Fernández MA
    Pediatrics; 2003 Feb; 111(2):E168-75. PubMed ID: 12563091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Surrogate endpoints in clinical studies exemplified by HIV infection].
    Furrer H
    Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1079-88. PubMed ID: 9691341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection.
    Goldman AI; Carlin BP; Crane LR; Launer C; Korvick JA; Deyton L; Abrams DI
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):161-9. PubMed ID: 8556398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural history of HIV infection: implications for the assessment of antiretroviral therapy.
    Corey L; Coombs RW
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S2-6. PubMed ID: 8093843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review.
    Stein DS; Korvick JA; Vermund SH
    J Infect Dis; 1992 Feb; 165(2):352-63. PubMed ID: 1346152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surrogate markers for assessing treatment response in HIV disease.
    Rathbun RC
    Ann Pharmacother; 1993 Apr; 27(4):450-5. PubMed ID: 8097416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neopterin and human immunodeficiency virus infection.
    Hofmann B
    Eur J Clin Chem Clin Biochem; 1993 Apr; 31(4):191-5. PubMed ID: 8100453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD
    N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate markers as surrogate endpoints in cancer research.
    Schatzkin A
    Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progression.
    Schechter M; Harrison LH; Halsey NA; Trade G; Santino M; Moulton LH; Quinn TC
    JAMA; 1994 Feb; 271(5):353-7. PubMed ID: 7904317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group.
    Hughes MD; Daniels MJ; Fischl MA; Kim S; Schooley RT
    AIDS; 1998 Oct; 12(14):1823-32. PubMed ID: 9792383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users.
    Alcabes P; Selwyn PA; Davenny K; Hartel D; Buono D; Schoenbaum EE; Klein RS; Friedland GH
    AIDS; 1994 Jan; 8(1):107-15. PubMed ID: 7912083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of the risk of development of acquired immunodeficiency syndrome within 24 months among gay men seropositive for human immunodeficiency virus type 1: a report from the Multicenter AIDS Cohort Study.
    Saah AJ; Muñoz A; Kuo V; Fox R; Kaslow RA; Phair JP; Rinaldo CR; Detels R; Polk BF
    Am J Epidemiol; 1992 May; 135(10):1147-55. PubMed ID: 1352940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.